Navigation Links
EntreMed's ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
Date:10/23/2008

ROCKVILLE, Md., Oct. 23 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presentation of preclinical data for its Aurora A/angiogenesis kinase inhibitor, ENMD-2076. The data were presented by John Tentler, Ph.D., Division of Medical Oncology, University of Colorado, at the 20th EORTC-NCI-AACR Annual Meeting being held this week in Geneva, Switzerland.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

ENMD-2076 is a novel kinase inhibitor with potent activity against Aurora A and a number of tyrosine kinases linked to cancer and inflammatory diseases. ENMD-2076 demonstrated strong antitumor effects in a xenograft model of human colon cancer. Tumor stasis was seen at dose levels of 100 mg/kg/day, and tumor regression was observed at doses of 200 mg/kg ENMD-2076 per day. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and post-study histological examination of tumors suggest that the antitumor effects of ENMD-2076 are exerted through a combination of antiangiogenic and antiproliferative actions. Further analysis using positron emission tomography (PET) demonstrated a substantial decrease in tumor metabolic activity in animals treated with ENMD-2076.

ENMD-2076 exerts its effects through multiple mechanisms of action, including antiproliferative activity and the inhibition of angiogenesis. ENMD-2076 has demonstrated substantial dose-dependent efficacy as a single agent, including tumor regression, in multiple xenograft models (e.g. breast, colon, leukemia). Aurora kinase
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
2. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
3. SuperGens MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy
4. SAFC Hitech(TM) Successfully Demonstrates Device-Quality GST Precursors For Phase Change Memory Applications
5. Grid Dynamics Demonstrates Linear Scalability up to 512 Nodes with GridGain Software on Amazon EC2 Cloud
6. First semiconductor-based PET scanner demonstrates potential to aid in early diagnosis of disease
7. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
8. ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Metastatic Pancreatic Cancer
9. Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Trial
10. ANX-530 Demonstrates Equivalent Pharmacokinetics to Navelbine(R) in a Registrational Bioequivalence Clinical Study
11. Bringing a New Rhythm to Cardiology Workflow: Siemens Demonstrates Answers to Cardiologys Toughest Questions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015 Axovant Sciences Ltd. (NYSE:  AXON), ... dementia, today announced upcoming presentations at three investor conferences: ... Baird 2015 Healthcare Conference in New York ... September 10 at 2:00 PM at the BioCentury NewsMakers Conference ... Broadway Hotel & Conference Center , Thursday, September 17 ...
(Date:9/2/2015)... Sept. 2, 2015 Research and ... addition of Jain PharmaBiotech,s new report ... their offering. An increasing ... biotechnology industries is anticipated. Nanotechnology will be ... - from formulations for optimal delivery to ...
(Date:9/2/2015)... ANN ARBOR, Mich. and LIBERTYVILLE, Ill. (PRWEB) , ... ... ... NSF International, a leading provider of regulatory compliance, quality systems, ... acquired Avarent LLC, a consulting firm with expertise in medical device products/processes ...
(Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "DNA ... their offering. This report briefly reviews ... technologies, and their applications. Current large and small ... them. Various applications of sequencing are described including ...
Breaking Biology Technology:Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2
... ... packaging machinery manufacturer, Sepha Ltd. is breaking into one of the world’s ... and de-blistering machines for the first time there at the ... of its presence at Interphex, Sepha has already received very positive ...
... 29 /PRNewswire-Asia/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL ... Purchase Plan which,closed on 24 June 2009. Shareholders of ... worth of shares each at the $2.35 price,paid by institutional ... A total of 1,584 shareholders participated in the plan under ...
... BD (Becton, Dickinson and Company) (NYSE: BDX ) ... third fiscal quarter 2009 earnings conference call on Thursday, July 30, ... release detailing the quarter,s earnings earlier that morning. , , ... be accessible through BD,s website at www.bd.com/investors ...
Cached Biology Technology:Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland 2Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland 3Pharmaxis Closes Share Purchase Plan 2
(Date:8/6/2015)... Aug. 6, 2015  Today, U.S. Congressman ... Crossmatch ™ to learn firsthand how Silicon Valley ... Crossmatch is a world leader in multi-factor identity ... are helping federal agencies and commercial organizations achieve ... "The vast majority of network breaches ...
(Date:8/6/2015)... Aug. 6, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced collaboration with Microsoft on ... 10. Microsoft leveraged Synaptics, deep expertise in human ... Through stringent testing, Synaptics, advanced ... with Microsoft,s Precision TouchPad (PTP) specification empowering OEMs ...
(Date:8/5/2015)... New York , August 5, 2015 ... market report titled "Facial Recognition Market - Global Industry ... 2022", the global market for facial recognition is forecast ... is driven by increased demand for surveillance systems by ... the rising number of crimes and terrorist activities across ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... lead to climate change adaptation practices in a ... agriculture has the potential to increase sustainable productivity, ... impacts and mitigate climate change through greenhouse gas ... the lead expert on climate change at the ...
... Most of us would agree that prevention is better ... Clinical Rehabilitation , published by SAGE, indicate that a costly ... in Finland had no measurable effect. , The research was ... 872 participants and their 2440 matched controls for up to ...
... discovery is a step toward implantable replacement cartilage, holding ... osteoarthritis, sports injuries and accidents. Self-assembling sheets ... with growth factor formed thicker, stiffer cartilage than previous ... have found. A description of the research is published ...
Cached Biology News:Climate-smart agriculture should be livelihood-smart too 2Climate-smart agriculture should be livelihood-smart too 3Costly intervention program has no measurable effect on early retirement 2Costly intervention program has no measurable effect on early retirement 3Engineering cartilage replacements 2Engineering cartilage replacements 3
... DeCypher combines enterprise-scale sequence analysis software with ... bioinformatics analyses. With DeCypher, you can perform searches ... ESTs vs NCBI NT database in under 6 ... to genomic DNA Use HMM analysis ...
...
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
...
Biology Products: